ライフサイエンスコーパス: shingles

1 aricella (chickenpox) and herpes zoster (HZ, shingles).

2 of varicella (chickenpox) and herpes zoster (shingles).

3 ricella (chickenpox) and herpes zoster (HZ) (shingles).

4 ative agent of chickenpox and herpes zoster (shingles).

5 th varicella (chickenpox) and herpes zoster (shingles).

6 40 years, it can give rise to herpes zoster (shingles).

7 ganglia, reactivates to cause herpes zoster (shingles).

8 common pathogen that causes chicken pox and shingles.

9 lla-zoster virus (VZV) causes chickenpox and shingles.

10 la-zoster virus (VZV) causes chicken pox and shingles.

11 n of VZV causes herpes zoster, also known as shingles.

12 utaneous and genital herpes, chickenpox, and shingles.

13 lla-zoster virus (VZV) causes chickenpox and shingles.

14 hout postherpetic neuralgia after unilateral shingles.

15 lla-zoster virus (VZV) causes chickenpox and shingles.

16 443) about their histories of chickenpox or shingles.

17 reactivates as herpes zoster, referred to as shingles.

18 iquitous pathogen that causes chickenpox and shingles.

19 aricella (chickenpox) and herpes zoster (HZ [shingles]).

20 cerebrovascular events, 205 (CI: 183, 230); shingles, 140 (CI: 104, 184); diabetic polyneuropathy, 5

21 the present vaccine can reactivate and cause shingles, a VZV vaccine based on the ORF63 mutant virus

22 sinusitis/otitis media, frequent episodes of shingles, a widespread fungal nail infection, fungal der

23 a mean density of 339 +/- 97 neurites/mm2 in shingles-affected epidermis compared with a density of 1

24 ree of the most important diseases of aging: shingles, Alzheimer's disease and atherosclerotic cardio

25 onset glioma and histories of chickenpox and shingles among 462 cases and 443 controls in the San Fra

26 that vaccination can reduce the incidence of shingles and might prove effective in patients with Alzh

27 Ms A is a 70-year-old woman with shingles and Ramsay-Hunt syndrome who presented to the e

28 as an antimicrobial agent in algae resistant shingles and treated wood is not expected to pose signif

29 ng materials such as algae-resistant roofing shingles and treated wood products for decks, fences, an

30 Release rates from algae-resistant shingles and treated wood were defined based on surface

31 virus, is the causative agent of chickenpox, shingles, and postherpetic neuralgia.

32 Shingles can cause chronic neuropathic pain (postherpeti

33 Herpes zoster (shingles) causes significant morbidity in immune comprom

34 associated procedures, including chickenpox, shingles, cold sores, mononucleosis, mumps, hepatitis B,

35 ss of vaccinations to prevent chickenpox and shingles, combined with the extremely low incidence of a

36 e occurred despite the lack of contralateral shingles eruptions or pain, correlated with the presence

37 For algae-resistant shingles, exposures did not exceed benchmarks in any med

38 nating immunocompetent patients who have had shingles has not been examined.

39 e evaluated from the site of maximum pain or shingles involvement, the homologous contralateral locat

40 cation, and a site on the back, distant from shingles involvement.

41 eas a vaccine is available for prevention of shingles, its efficacy declines with age.

42 npox (odds ratio = 0.4, 95% CI 0.3-0.6), and shingles (odds ratio = 0.5, 95% CI 0.3-0.8).

43 .4, 95% confidence interval (CI) 0.3-0.6) or shingles (odds ratio = 0.5, 95% CI 0.3-0.8).

44 a neuroattenuated vaccine candidate against shingles or a vector for delivery of other antigens.

45 and may reactivate later in life, leading to shingles or inflammatory diseases of the nervous system

46 l arteries after either reactivation of VZV (shingles) or primary infection (chickenpox).

47 The Shingles Prevention Study (SPS) demonstrated zoster vacc

48 The Depression Substudy of the Shingles Prevention Study (SPS) was designed to evaluate

49 After completion of the Shingles Prevention Study (SPS; Department of Veterans A

50 The Shingles Prevention Study (SPS; Department of Veterans A

51 The Shingles Prevention Study demonstrated that HZ vaccine s

52 The Shingles Prevention Study showed that a varicella-zoster

53 Individuals afflicted with shingles risk developing the painful condition of posthe

54 presence and severity of ongoing pain at the shingles site, and did not extend to the distant site.

55 neuralgia (PHN) is a common complication of shingles that manifests as prolonged excruciating pain,

56 le neuropathic pain following herpes zoster (shingles) that eludes effective treatment in many patien

57 f VZV reactivation are observed in the skin (shingles), the number and functional capacity of cutaneo

58 us and the causative agent of chickenpox and shingles, the latter being particularly associated with

59 kenpox) during primary infection and zoster (shingles) upon reactivation.

60 er adults immunized with the live attenuated shingles vaccine Zostavax.

61 ded by a doctor among those who received the shingles vaccine, 98.0% (95% CI: 95%-100%), was signific

62 g varicella (chicken pox) and herpes zoster (shingles), we generated a full-length infectious bacteri

63 glia, and reactivates decades later to cause shingles (zoster) and other neurologic complications.

64 irus that causes chicken pox (varicella) and shingles (zoster).

65 entire neuraxis, and reactivates to produce shingles (zoster).

66 glia, and reactivates decades later to cause shingles (zoster).